Soulandi Djorwé, Laboratory of Physiopathology and Molecular Genetics, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca (Morocco). Avenue Cdt Driss El Harti, PB 7955 Sidi Othman Casablanca (Morocco)Follow
Amale Bousfiha, Laboratory of Physiopathology and Molecular Genetics, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca (Morocco). Avenue Cdt Driss El Harti, PB 7955 Sidi Othman Casablanca (Morocco)
Néhémie Nzoyikorera, National Reference Laboratory, National Institute of Public Health, Burundi
Joseph Nyandwi, Département de Médecine, Faculté de Médecine, Université du Burundi, Burundi
Bellamine Kawthar, Bourgogne Laboratory of Medical and Scientific Analysis, 136, residence belhcen, Bd Bourgogne, Casablanca (Morocco)
Abderrahim Malki, Laboratory of Physiopathology and Molecular Genetics, Faculty of Sciences Ben M'Sik, Hassan II University of Casablanca (Morocco). Avenue Cdt Driss El Harti, PB 7955 Sidi Othman Casablanca (Morocco)

Background: The emergence of SARS-CoV-2 variants has significantly increased the number of cases of COVID-19 among vaccinated individuals, raising concerns about the effectiveness of current vaccines. The aim of this study was to analyze the SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologues and heterologous booster vaccinations with these vaccines, as well as the profiles of reinfected patients. Methods: We analyzed retrospectively 1082 patients vaccinated or unvaccinated with BNT162b2, BBIBP-CorV, and/or ChAdOx1nCoV-19 vaccines to determine their SARS-CoV2 infection statuses using the reverse transcription-polymerase chain reaction (RT-PCR) in addition to their clinical features. The infection risks of patients receiving the different vaccine regimens were compared using multivariate logistic regression analysis, comparing the adjusted OR of a positive COVID-19 test result. Results: Among 596 vaccinated patients, 53%(n=286) tested positive for SARS-CoV-2 and 57%(n=310) tested negative. Among positive cases, 10 were reinfection cases. The risk of SARS-CoV-2 infection was 1.6 (adj. OR) for patients who received one dose compared with those who received two doses (95% CI=1.3-1.8; p

Djorwé, Soulandi; Bousfiha, Amale; Nzoyikorera, Néhémie; Nyandwi, Joseph; Kawthar, Bellamine; and Malki, Abderrahim (2023) "Evaluation of SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologous and heterologous booster vaccinations with these vaccines and evaluation of SARS-CoV-2 reinfection profiles," BioMedicine: Vol. 13 : Iss. 3 , Article 4.
DOI: 10.37796/2211-8039.1412